Condition: Diabetes Mellitus, Type 2 · Sponsor: Novo Nordisk A/S
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Arkansas Clinical Research | Little Rock, Arkansas, United States | — |
| Paradigm Clinical Research | San Diego, California, United States | — |
| Encompass Clinical Research_Spring Valley | Spring Valley, California, United States | — |
| Diablo Clinical Research, Inc. | Walnut Creek, California, United States | — |
| Future Medical Research | Longwood, Florida, United States | — |
| New Horizon Research Center | Miami, Florida, United States | — |
| Clinical Site Partners Kendall Flourish Research | Miami, Florida, United States | — |
| West Orange Endocrinology | Ocoee, Florida, United States | — |
| Center for Diab,Obes & Metab | Pembroke Pines, Florida, United States | — |
| American Research Centers of Florida | Pembroke Pines, Florida, United States | — |
| Hope Clin Res & Wellness | Conyers, Georgia, United States | — |
| Elevate Clinical Research | Gurnee, Illinois, United States | — |
+ 49 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.